The use of scopolamine to temporarily disrupt the neurotransmission by occupying the acetylcholine binding site in the muscarinic receptors induces amnesia, which is generally used in AD animal models and human clinical trials for developments of ACE inhibitors [13,14,15]. This evidence concerns the gene ACE and Alzheimer disease.